Pfizer's third-quarter earnings just came in, and guess what? They're way better than expected! The company's making a lot more money, thanks to a big demand for their COVID-19 treatments. Their best-selling drug, Paxlovid, brought in a whopping $2. 7 billion in the third quarter alone. This is a ma
Pfizer, a major player in the pharmaceutical industry, has recently shared more details about its weight loss drug pipeline. This comes as part of their efforts to compete in the growing market for weight loss medications, currently dominated by Novo Nordisk and Eli Lilly. These companies have found
Pfizer, one of the world's largest pharmaceutical companies, surprised many analysts with its third-quarter earnings. The company reported earnings of $1. 06 per share, well above the expected $0. 61. Sales also exceeded expectations, coming in at $17. 7 billion compared to the projected $14. 92 bil
Pfizer, a pharmaceutical giant, has been in the spotlight lately. Investors have been discussing the company's future under CEO Dr. Albert Bourla. Recently, an activist investor named Starboard Value shared some thoughts on Pfizer. They pointed out issues but also emphasized the company's potential.
Pfizer Inc. has shared some exciting news! Their new medicine, HYMPAVZI (marstacimab-hncq), just got the green light from the U. S. Food and Drug Administration. This medication is designed to help people with hemophilia A and B prevent or reduce bleeding episodes. Hemophilia is a rare condition th
Imagine this: a big pharma company like Pfizer is in the spotlight, not for a new drug, but for some serious boardroom drama. Activist investor group Starboard Value has accused Pfizer of some heavy-handed tactics. They claim that Pfizer or its advisors threatened former CEO Ian Read and ex-CFO Fran
The stock market is about to open, and investors need to be prepared for what's coming. Here are the top 5 things you need to know before the market opens on Monday. So, what's the big news? Well, the Federal Reserve is set to make a crucial decision on interest rates, which could have a significan
The news of Pfizer's positive midstage trial results for its experimental drug, ponsegromab, has sent shockwaves through the medical community. This monoclonal antibody has shown remarkable promise in combating cancer cachexia, a life-threatening condition that afflicts approximately 9 million peopl
